Page 4 - Affimed News Today

Affimed (NASDAQ:AFMD – Get Rating)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.97 and traded as low as $0.65. Affimed shares last traded at $0.65, with a volume of 15,772,533 shares traded. Analyst Ratings Changes A number […]

Boone Capital Management LLC bought a new position in shares of Affimed (NASDAQ:AFMD – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,869,744 shares of the biopharmaceutical company’s stock, valued at approximately $3,558,000. Affimed makes up about 1.8% of […]

Affimed (NASDAQ:AFMD – Get Rating) had its price objective trimmed by HC Wainwright from $6.00 to $5.00 in a research note published on Monday morning, The Fly reports. A number of other brokerages have also issued reports on AFMD. StockNews.com began coverage on shares of Affimed in a research note on Thursday, May 18th. They […]

Affimed (NASDAQ:AFMD – Get Rating) – Equities researchers at HC Wainwright increased their Q2 2023 earnings estimates for Affimed in a research report issued on Wednesday, May 24th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.25). HC […]

Affimed (NASDAQ:AFMD – Get Rating) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average […]

HEIDELBERG, Germany, May 22, 2023 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2023... | May 22, 2023

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other analysts have also issued reports about the company. Wells Fargo & Company reiterated an overweight rating and set a $7.00 price target on shares of […]

Research analysts at StockNews.com started coverage on shares of Affimed (NASDAQ:AFMD – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Several other analysts have also recently commented on AFMD. Stifel Nicolaus reduced their price target on Affimed from $2.00 to $1.00 […]

Affimed (NASDAQ:AFMD – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Tuesday, May 23rd. Analysts expect Affimed to post earnings of ($0.22) per share for the quarter. Affimed (NASDAQ:AFMD – Get Rating) last posted its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.22) earnings […]

HEIDELBERG, Germany, May 16, 2023 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will... | May 16, 2023